Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Withdrawn before enrolling · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The purpose of this study is to determine the recommended dose for the combination of dasatinib and bendamustine in chronic lymphocytic leukemia (CLL).

Key facts

Study ID

NCT00872976

Run by

Bristol-Myers Squibb

People needed

0

Starts

2009-05-01

Expected to finish

2011-12-01

Last updated by the study team

2013-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Unwilling or unable to use an acceptable method to avoid pregnancy
• Uncontrolled or significant cardiovascular disease, including prolonged QTc interval
• History of significant bleeding disorder, unrelated to CLL
• Prior concurrent malignancy
• Drugs that generally accepted to have the risk of causing Torsades de Pointes
• Autoimmune hemolytic anemia requiring therapy or transfusion support
• Autoimmune thrombocytopenia requiring steroid therapy or transfusion support
• Richter's Syndrome
• Transformation to prolymphocytic leukemia

Where it is running

• Local Institution — New Hyde Park, New York, United States
• Local Institution — Columbus, Ohio, United States
• Local Institution — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.